Question 1

Is Mounjaro more effective than Ozempic for weight loss?

Accepted Answer

Yes, on direct head-to-head data. SURPASS-2 (Frías 2021 NEJM, PMID 34170647) randomized 1,879 T2D patients to Mounjaro 5/10/15 mg or Ozempic 1 mg for 40 weeks. Mounjaro 15 mg produced -11.2 kg vs Ozempic 1 mg -5.7 kg — a ~2x difference. Even the lowest Mounjaro dose (5 mg) beat Ozempic 1 mg numerically. Note SURPASS-2 used Ozempic's T2D-max 1 mg dose, not the 2 mg dose later approved; real-world gaps may be smaller at matched higher doses, but no head-to-head at Ozempic 2 mg has been published.

Question 2

Is Ozempic FDA-approved for weight loss?

Accepted Answer

No. Ozempic is FDA-approved only for type 2 diabetes and (since 2020) for reducing major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule (semaglutide) at a higher 2.4 mg dose is sold as Wegovy for chronic weight management. Prescribing Ozempic for weight loss without T2D is off-label and rarely covered by insurance. See the Ozempic FDA prescribing information for the full indication statement.

Question 3

Which has better cardiovascular outcomes?

Accepted Answer

Ozempic, by a wide evidence margin. SUSTAIN-6 (Marso 2016 NEJM, PMID 27633186) randomized 3,297 T2D patients at high CV risk to semaglutide vs placebo and showed a 26% reduction in major adverse cardiovascular events (HR 0.74, p=0.02 for superiority) over a median 2.1 years. Mounjaro's dedicated CV outcomes trial (SURPASS-CVOT) is comparing tirzepatide to dulaglutide and reads out in 2027 — until then, Mounjaro has no peer-reviewed MACE-reduction evidence.

Question 4

What's the difference in mechanism?

Accepted Answer

Ozempic is a pure GLP-1 receptor agonist. Mounjaro is a dual agonist that activates both the GLP-1 and the GIP (glucose-dependent insulinotropic polypeptide) receptors. The GIP component appears to add insulin-sensitizing and possibly central appetite-modulating effects beyond GLP-1 alone, which is the leading mechanistic hypothesis for Mounjaro's larger weight-loss and A1C effects seen in SURPASS-2 (PMID 34170647). Both drugs are once-weekly subcutaneous injections.

Question 5

Can I switch from Ozempic to Mounjaro?

Accepted Answer

Yes — and many endocrinologists do, particularly when patients plateau at Ozempic 2 mg or need additional A1C lowering. Standard practice is to stop Ozempic and restart at Mounjaro 2.5 mg (the introductory non-therapeutic dose) regardless of prior Ozempic dose, then titrate up every 4 weeks. The molecules are different (dual GIP/GLP-1 vs GLP-1 alone) and no dose-equivalence table exists. Expect a brief GI-side-effect period during re-titration.

Question 6

Which is cheaper without insurance?

Accepted Answer

Both have similar US wholesale acquisition costs (~$1,000/mo) and neither has a true cash-pay program matching Wegovy or Zepbound's $349-$499 manufacturer-direct tiers. Ozempic's manufacturer savings card (NovoCare) is limited to commercially insured patients with T2D — cash payers and Medicare/Medicaid patients are excluded. Lilly's Mounjaro savings card has the same commercial-insurance restriction. Expect to pay ~$900-$1,100/mo retail for either if uninsured; check GoodRx and grocery-pharmacy programs for partial discounts.

Field	Ozempic	Mounjaro
Mean weight loss (TBWL, head-to-head)	-5.7 kg / 40 wks (Ozempic 1mg)	-11.2 kg / 40 wks (Mounjaro 15mg)
A1C reduction (SURPASS-2)	-1.86% (Ozempic 1mg)	-2.30% (Mounjaro 15mg)
Mechanism	GLP-1 receptor agonist	Dual GIP / GLP-1 agonist
FDA-approved indication	Type 2 diabetes; CV risk reduction in T2D + CVD	Type 2 diabetes (weight management requires Zepbound)
Cardiovascular outcome	MACE -26% (SUSTAIN-6, 2016)	SURPASS-CVOT pending 2027
Dosing	Once-weekly subq 0.25-2.0 mg (4-step titration)	Once-weekly subq 2.5-15 mg (6-step titration)
Most common adverse event	Nausea (~20% at 1mg; SUSTAIN-7)	Nausea (~22% at 15mg; SURPASS-2)
Cash price (US, ~2026)	~$998/mo retail (no manufacturer cash-pay program)	~$1,069/mo WAC (Lilly savings card for commercial)

Ozempic vs Mounjaro (2026): SURPASS-2 Head-to-Head, A1C, Cost

The verdict

Side-by-side comparison

Frequently asked questions